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Abstract
Objective: To investigate the potential involvements of E-cadherin and b-catenin in meningioma.
Methods: Immunohistochemistry staining was performed on samples from patients with meningioma. The results were
graded according to the positive ratio and intensity of tissue immunoreactivity. The expression of E-cadherin and b-catenin
in meningioma was analyzed by its relationship with WHO2007 grading, invasion, peritumoral edema and postoperative
recurrence.
Results: The positive rates of E-cadherin in meningioma WHO I, II, III were 92.69%, 33.33% and 0, respectively, (P,0.05);
while the positive rates of b-catenin in meningioma WHO I, II, III were 82.93%, 33.33% and 20.00%, respectively, (P,0.05).
The positive rate of E-cadherin in meningioma without invasion (94.12%) was higher than that with invasion (46.67%)
(P,0.05). The difference in the positive rate of b-catenin between meningioma without invasion (88.24%) and meningioma
with invasion (33.33%, P,0.05) was also statically significant. The positive rates of E-cadherin in meningioma with
peritumoral edema 0, 1, 2, 3 were 93.75%, 85.71%, 60.00% and 0 respectively, (P,0.05); the positive rates of b-catenin in
meningioma with peritumoral edema 0, 1, 2, 3 were 87.50%, 85.71%, 30.00% and 0 respectively, (P,0.01). The positive rates
of E- cadherin in meningioma with postoperative recurrence were 33.33%, and the positive rate with postoperative non-
recurrence was 90.00% (P,0.01). The positive rates of b-catenin in meningioma with postoperative recurrence and non-
recurrence were 11.11%, 85.00%, respectively (P,0.01).
Conclusion: The expression levels of E- cadherin and b-catenin correlated closely to the WHO 2007 grading criteria for
meningioma. In atypical or malignant meningioma, the expression levels of E-cadherin and b-catenin were significantly
lower. The expression levels of E- cadherin and b-catenin were also closely correlated with the invasion status of
meningioma, the size of the peritumoral edema and the recurrent probabilities of the meningioma, all in an inverse
correlationship. Taken together, the present study provided novel molecular targets in clinical treatments to meningioma.
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Introduction
Meningioma originates from the derivatives of meninges and
arachnoid cap cells. Its incidence as primary intracranial tumors is
very high (15–20%), ranked just behind the cerebral glioma [1,2].
The biological characteristics of meningioma are diverse. Most of
tumors show retarded growth, but a small portion also display
invasive growth. Most meningiomas can be cured by complete
surgical removal, although there are always the risks of recurrence.
The present theory on the occurrence and the development of
meningiomas include polygenetic and multiple molecular factors
[3,4]. For example, recent studies suggested that E-cadherin-
mediated cell-cell adhesion is critical in these processes [5,6]. The
objectives of this study were to investigate the expression levels of
E-cadherin and b-catenin in meningioma with both temporal and
spatial information, in order to determine their pathological
significance in tumor invasion, formation of peritumoral edema,
and postoperative recurrence. The results showed that both the
two molecules are tightly associated in meningioma and could




All specimens involved in this study were collected from 49
meningioma patients with university guidelines carefully followed
(approved by Taizhou Hospital ethic committe for medical
research in using clinical human samples). Written permissions
from patients were obtained. These operative specimens came
from the Affiliated Municipal Hospital at Taizhou Medical
College and Sir Run Run Shaw Hospital at Zhejiang University.
All the patients were diagnosed as meningioma in formal
pathological reports between Jan 2003 and Sep 2005.
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Eighteen cases were male, and 31 cases were female. The age
range was 20 to 75 years, and the average age was 56.3617.1
years. The length of time for which the patients had meningioma
varied from 5 years to 2 days. The first symptoms were as follows:
increased intracranial pressure (12 cases), visual disturbance (7
cases), disorder of limb activity (20 cases), hearing disorder (4
cases), seizure (6 cases), and other (10 cases). Cranial MRIs
revealed the tumor locations as follows: cerebral hemisphere (15
cases), pardsagittal (17 cases), and cerebellopontine (5 cases) Angle,
6 cases in sphenoid ridge, 6 cases in sellar region; The tumor size
was as follows: ,3 cm (8 cases), 3,6 cm (25 cases), .6 cm (16
cases). The dural tail sign was not obvious in 20 cases and was
obvious in 29 cases. All 17 cases of pardsagittal tumors had MR
venous angiography(MRV), and 2 cases underwent DSA. The
results showed that no obstructed sagittal sinus or thrombosis was
present. In five cases, the tumors were closely related to the
cortical draining veins, but it was easy to separate the tumors and
veins during the operation, and there were no obstructions or
thrombosis with cortical draining veins. In the samples we studied,
22 cases were Simpson resection grade I, and the other 27 cases
were Simpson resection grade II. Invasive tumor was defined
according to whether the tumor had invaded the pia mater and
skull. This was ascertained by surgical findings and pathological
examination. In the invasive group, the tumors had invaded the
pia mater or the skull and the arachnoidal cleavage plane had
disappeared, while in the non-invasive group, the tumors had not
invaded the pia mater or the skull and the arachnoidal cleavage
plane was well preserved. According to these criteria, 15 cases
were classified as invasive. All of them, the tumor .3cm diameter
2 cases, the tumor 3–6cm diameter 8 cases, the tumor .6c m
diameter 5 cases. Goldman’s method was used to classify
peritumoral edema [7]. According to this classification method,
16 cases were 0 grade without obvious edema, 21 cases were grade
1 with an edema zone ,2cm, 10 cases were grade 2 with an
edema zone $2cm but restricted to the hemisphere, 2 cases were
grade 3 with an edema zone more than the hemisphere. The
resected pathological specimens were hematoxylin-eosin (HE)
stained. The histological type and grade of the specimens were
classified according to the WHO 2000 standard. Forty one cases
were benign meningiomas (WHO grade I), 3 cases were atypical
meningiomas (WHO grade II), and 5 cases were malignant
meningiomas (WHO grade III). Of the benign meningiomas, 10
were epithelial, 5 were transitional, 14 cases were fibrillar, 7 were
glit, 2 were angiomas, and 3 were microcystic. Every case included
a follow-up visit by the out-patient service or by telephone and
letter. The follow-up intervals ranged from 18,52 months, and
the mean follow-up time was 40.9619.3 months. Upon follow-up,
there were 9 relapses, 3 cases had been reoperated, 4 cases had
been treated by a gamma knife, and the other 2 cases had been
under continuous observation.
Immunohistochemistry
The expression levels of E-cadherin and b-catenin were
measured by immunohistochemical staining and En Vision.
Tissues were prepared as paraffin sections. Prior to immunohis-
tochemistry, the sections were deparaffinized with xylene,
dehydrated with ethanol, and deoxidised with methanol. The
sections were then prepared in a pressure cooker to 121uC for
2 minutes in citrate buffer solution to restore the antigen
immunoreactivity. Then the sections were washed in PBS prior
to incubation with primary mice monoclonal antibodies of E-
cadherin (1:50, Shanghai Gene Tech Co.) and b-catenin (1:200,
Shanghai Gene Tech Co.) overnight at room temperature. Then
the sections were processed for DAB visualization. The sections
were then mounted with permount medium and observed under a
light microscope.
Criteria in analyzing the staining pictures
The expression of E-cadherin was located in either the
membrane or cytoplasm of meningioma cells, more commonly
in the former. The expression of b-catenin was located in the
membrane, cytoplasm, and perinuclear granules [8]. The
expression strength was analyzed and graded based on the positive
ratio and intensity of immunoreactivity [9]. The positive cells were
stained light brownish-yellow to chocolate–brown, and the
intensity of the immunoreactive products was scored under a high
power microscopic as follows: no expression, 0; yellowish, 1;
imperial yellow, 2; and brown, 3. The positive ratio was scored as
follows: positive cells ,5%, 0; positive cells 5–10%, 1; positive cells
11–50%, 2; positive cells 51–80%, 3; positive cells .80%, 4. The
two scores were multiplied, and the IRS (values from 0–12) was
determined as follows: 0 (2), 1–3 (+), 4–6 (++), and .6( +++). We
Table 1. The expression of E-cadherin and b-catenin with the




cadherin expression of b-catenin
2 + ++ +++ 2 + ++ +++
fibrillar 14 3 4 5 2 3 3 4 4
transitional 5 0 3 1 1 1 1 2 1
epithelial 10 0 4 3 3 2 1 3 4
microcystic 3 0 1 1 1 0 1 2 0
angioma 2 0 0 2 0 0 0 2 0
g l i t 70 33 1 1 23 1
atypical 3 2 1 0 0 3 0 0 0
malignant 5 5 0 0 0 4 1 0 0
doi:10.1371/journal.pone.0011231.t001
Table 2. The expression levels of E-cadherin and b-catenin in different pathological grades of meningioma.
pathological grade n expression of E-cadherin expression of b-catenin
2 + ++ +++ 2 + ++ +++
I 4 131 51 58 781 61 0
I I 32 100 2 0 10
I I I 55 000 4 1 00
doi:10.1371/journal.pone.0011231.t002
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observation objects then decided the results of determining.
Statistical analyses
Statistical analyses were carried out using SPSS 11.0 software.
The comparison of the expression strength of E-cadherin and b-
catenin with the differentiated pathological types was performed
by the rank sum test. The comparison of the positive ratio of E-
cadherin and b-catenin with the differentiated WHO 2000
grading, incidence of invasion, level of peritumoral edema, and
postoperative recurrence was performed by the Chi-square test.
P,0.05 was considered as statistically significant.
Results
The expression levels of E-cadherin and b-catenin and
their co-relationship to meningioma pathological types
(Table 1)
We investigated the expression levels of E-cadherin and b-
catenin among different types of meningioma. We found that their
expression levels were not statistically different between each other
(x
2=5.649, 6.274, respectively; P.0.05). This suggested that E-
cadherin and b-catenin could be common molecules participated
in the development of diverse meningioma.
The expression results for E-cadherin and b-catenin with
the different pathological grades of meningioma (Table 2)
To understand if the amounts of E-cadherin and b-catenin
could contribute to the servility of meningioma, we graded the
samples of meningiomas following WHO2007 standards. We
found that the positive rates of E-cadherin were 92.69%(38/41),
33.33%(1/3), and 0 respectively, for grade I, II, and III
(x
2=28.42, P,0.01). The positive rates of b-catenin for grades
I, II, and III were 82.93%(34/41), 33.33%(1/3), and 20%(1/5),
respectively, and these differences were significantly different
(x
2=13.09, P,0.05).
The expression results for E-cadherin and b-catenin with
differential invasion of meningioma (Table 3)
We further asked if the expression levels of the two proteins
could contribute the invasion ability of the tumor. We found
significant differences in the expression levels of E-cadherin and b-
catenin between invasive or non-invasive meningioma (P,0.05).
This strongly suggested that E-cadherin and b-catenin could be
potentially negative regulators of the tumor invasion.
The expression results for E-cadherin and b-catenin in
different grades of peritumoral edema (Table 4)
We found that the positive rates of E-cadherin were 93.75%
(15/16), 85.71% (18/21), 60%(6/10) and 0, respectively for
peritumoral edema graded at 0,1,2,3 (x
2=11.22, P,0.05). The
positive rates of b-catenin for grade 0, 1, 2, and 3 were87.50%(14/
16), 85.71% (18/21), 30%(3/10), and 0, respectively (x
2=17.54,
P,0.01).
The relationship of the expression levels of E-cadherin
and b-catenin with the postoperative recurrence of
meningioma (Table 5)
Because the expression levels of E-cadherin and b-catenin could
reflect the invasive ability of the tumor cells, therefore they might
also be implicative for post-operative recurrence. We therefore
investigated the association between expression levels of of E-
cadherin and b-catenin in our study. We found that the expression
levels of of E-cadherin and b-catenin in postoperative recurrence
cases were 33.33% and 11.11%, respectively; and for postoper-
ative non-recurrence cases they were 90% and 85%, respectively.
In both cases, the differences were significantly different
(x
2=15.49 for postoperative recurrence cases, and 12.84 for
postoperative non-recurrence cases, P,0.01).
Table 3. Relationship between E-cadherin and b-catenin expression levels and the aggressiveness of meningioma.
invasion n expression of E-cadherin expression of b-catenin
2 + ++ +++ positive rate 2 + ++ +++ positive rate
invasion 15 8 5 1 1 46.67% 10 4 1 0 33.33%





Table 4. The expression levels of E-cadherin and b-catenin







2 + ++ +++ 2 + ++ +++
01 6 1 3 5 7 2 2 2 1 0
1 2 1371 01 341 40
21 0 4 6 0 0 7 3 0 0
3 2 2 0 00 2 0 00
doi:10.1371/journal.pone.0011231.t004
Table 5. The expression levels of E-cadherin and b-catenin
with the postoperative recurrence of meningioma.
recurrence n expression of E-cadherin expression of b-catenin
2 + ++ +++ 2 + ++ +++
y e s 96 20 1 8 0 0 1
no 40 4 14 15 7 6 9 16 9
doi:10.1371/journal.pone.0011231.t005
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the pathological grades of meningioma (Figure 1,6)
Figure 1: epithelia (WHO|grade)
E-cadherin z ðÞ , |200
Figure 2: epithelial (WHO|grade)
b-catenin z ðÞ , |200
Figure 3: fibrillar l (WHO|grade
E-cadherin zz ðÞ , |200
Figure 4: fibrillar l (WHO|grade)
b-catenin zz ðÞ , |200
Figure 5: epithelial (WHO|grade)
E-cadherin zzz ðÞ , |200
Figure 6: malignant (WHO|grade)
b-catenin z ðÞ , |200
Discussion
E-cadherin was a calcium-dependent cell-cell adhesion molecule
with pivotal roles in epithelial cell behavior, tissue development,
and suppression of cancer growth [10,11]. It was first discovered in
1995 by Berx et al. [12]. Cadherin depended on Ca
2+ for its
function and the structural rigidity; the extracellular amino-
terminus formed the ‘‘zipper-like’’ structure with that would act as
a cell tight junction. The intracellular carboxyl-terminus of the
cadherin molecule indirectly attached the cytoskeleton via catenin.
b-catenin, which was one of four known kinds of catenin, is a
multifunctional protein [13]. It directly joined to the cytoplasmic
terminal of E-cadherin and formed the E-cadherin/catenin
complex [14,15]. Disruption of this junction would lead to diverse
phenotypes, including loosed cell-to-cell contacts, morphological
Figure 1. E-cadherin immunostaining on tissue of epithelial
type of meningioma (WHO I grade), with amplification of 200X.
Expression level was determined as +.
doi:10.1371/journal.pone.0011231.g001
Figure 2. b-catenin immunostaining on tissue of epithelia type
of meningioma (WHO I grade), with amplification of 200X.
Expression level was determined as +.
doi:10.1371/journal.pone.0011231.g002
Figure 3. E-cadherin immunostaining on tissue of fibrillar 1
type of meningioma (WHO I grade), with amplification of 200X.
Expression level was determined as ++.
doi:10.1371/journal.pone.0011231.g003
Figure 4. b-catenin immunostaining on tissue of fibrillar 1 type
of meningioma (WHO I grade), with amplification of 200X.
Expression level was determined as ++.
doi:10.1371/journal.pone.0011231.g004
Figure 5. E-cadherin immunostaining on tissue of epithelial
type of meningioma (WHO I grade), with amplification of 200X.
Expression level was determined as +++.
doi:10.1371/journal.pone.0011231.g005
Figure 6. b-catenin immunostaining on tissue of malignant
type of meningioma (WHO III grade), with amplification of
200X. Expression level was determined as +.
doi:10.1371/journal.pone.0011231.g006
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of the cell contact inhibition. The changes in molecule structure
and function were directly related to the biological behavior of
tumor cells, affecting their detachment and re-adhesion.
The expression level of E-cadherin could be related to the
classification of astrocytomas. For this reason, an assessment of the
expression status of E-cadherin in astrocytomas could be one
important index in determining the prognosis of patients [16,17].
A previous study by Motta et al. examined the expression of E-
cadherin in astrocytoma and brain cells with non-CNS tumors
[18]. They found that the expression strength of E-cadherin in
low-grade astrocytomas (grade I–II) was higher than that
presented in high-grade astrocytomas (grade III–IV) (P,0.0001),
while the expression strength of E-cadherin in non-CNS tumors is
higher than that found in grade I astrocytomas.
The results of our research revealed remarkable differences in the
involvements of E-cadherin and b-catenin in different pathological
grades of meningioma. Moreover, these differences were statically
significant. As the pathological grade of meningioma increased, the
positive rates of E-cadherin and b-catenin in meningioma
decreased. The expression levels of the E-cadherin and b-catenin
were actually completely diminished in malignant meningioma. In
previous studies, Utsuki et al. tested specimens of 103 meningioma
and found that the expression levels of E-cadherin in 5 atypical
meningioma were all negative, 3 cases of the expressions of the b-
catenin were negative among them [19]. However E-cadherin and
b-catenin expression were positive in epithelial meningioma. In 10
of the 12 cases of invasive meningioma, the E-cadherin and b-
catenin expression levels were negative. Therefore they concluded
that the decrease in cell adhesion molecules was associated with the
increase in tumor cell proliferation and might contribute to invasive
ability of meningioma.
Tumor invasiveness and the presence of peritumoral edema
were the two major factors that would determine the clinical
management of meningioma. There were some biological,
physical, and chemical factors that contribute to the peritumoral
edema of meningioma [20]. In our studies, we found remarkable
differences in the positivity rates for E-cadherin and b-catenin
expression corresponding to different degrees of peritumoral
edema. As the expression of E-cadherin and b-catenin decreased,
possibilities of developing peritumoral edema would increase. We
therefore believe that there existed a mechanism in the
meningioma cell (even with the high degree of malignancy) which
could inhibit the expression of E-cadherin and b-catenin, leading
to the harmed cell-to-cell junctions, damaging of the tumor-brain
interface and the blood-brain barrier. Consequently, the menin-
gioma cells could infiltrate brain tissue and increase brain edema.
In cases that showed a deletion of E-cadherin and b-catenin, one
would expect serious brain edema and the clinical features of
intracranial hypertension. For this reason, clinical surgeons should
pay close attention to the intracranial pressure during a tumor-
removal operation.
The decrease or deletion of the expression of E-cadherin leads
to the loss of contact inhibition and unrestricted hyperplasia, the
loss of intercellular junction with, stronger invasive ability,
enhanced tumor cell diffusion and metastasis, as well as benign
tumor malignant transformation in some extreme cases
[21,22,23]. Erdemir F et al. tested specimens of bladder cancers
and found that 13 of the 25 stage T1a cases were recurrent and
that the positive rate of E-cadherin among them was only 30.7%
[24]. However, in the 12 non-recurrent cases, the positive rate of
E-cadherin was 75%. Among the stage T1b 27 cases, 25 of the 27
were recurrent, and the positive rate of E-cadherin was only 12%.
All these data suggested there was a close relationship between the
decreased expression of E-cadherin and recurrence of postoper-
ative bladder cancer. The results of our studies showed that the
positive rates of E-cadherin and b-catenin with postoperative
recurrence were both significantly lower when compared to those
of postoperative non-recurrent cases. We also tested E-cadherin
and b-catenin expression levels in pituitary adenoma and found
that E-cadherin and b-catenin expression levels were significantly
down-regulated and were related to the extent of invasive pituitary
adenoma. Pituitary adenoma recurred most easily when the
expression of E-cadherin and b-catenin were decreased (Liu et al.
Unpublished data).
In summary, the present study employed molecular biology and
immunohistochemistry tools to understand the potential involve-
ments of two cell-adhesion molecules in development and
invasiveness of meningioma, which provided novel targets for
pathological analyses as well as therapeutic drugs.
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